CHINA – Eccogene, a Shanghai, China-based clinical-stage biotechnology company, raised CNY180M (approx. $25M) in Series B Equity funding.
The round by co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital. The syndicate also included new investors Rockbleu Capital, YuFu Investment, Huajin Capital, Elikon Venture and existing investors Delos Capital, Oriza Seed Capital and Qingsong Capital.The company intends to use the funds for the development of its clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders.Led by CEO Jingye Zhou, Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on the discovery and development of translational medicine for metabolic and immune-related diseases.Eccogene’s clinical pipeline also includes ECC0509, a peripherally distributed SSAO/VAP-1 inhibitor, which is near completion of a Phase I clinical trial.12/06/2023
